Recipharm sells plants in France and the UK

By Brian Buntz | January 10, 2022

Recipharm has sold a solid-dose manufacturing plant in Fontaine-lès-Dijon, France to Astrea Pharma, a new contract development and manufacturing organization (CDMO).

Recipharm also announced that Pharmaron Beijing Co. has acquired Aesica Pharmaceuticals Ltd, which Recipharm had acquired about a year ago.

Historically, the plant in France has focused on manufacturing and packaging tablets and capsules.

The divestment of the facility will improve Recipharm’s financial position and streamline its operations, according to the company’s CEO Marc Funk.

The Aesica Pharmaceuticals Ltd facility in Cramlington near Newcastle has focused on manufacturing various active pharmaceutical ingredients.

Pharmanon chairman and CEO Dr. Boliang Lou said the acquisition will boost its chemistry, manufacturing and controls (CMC) capabilities. Pharmanon also has invested in ramping up its API manufacturing.

About The Author

Brian Buntz

The pharma and biotech editor of WTWH Media, Brian is a veteran journalist with more than 15 years of experience covering an array of life science topics, including clinical trials, drug discovery and development and medical devices. Before coming to WTWH, he served as content director focused on connected devices at Informa. In addition, Brian covered the medical device sector for 10 years at UBM. At Qmed, he overhauled the brand’s news coverage and helped to grow the site’s traffic volume dramatically. He had previously held managing editor roles on two of the company’s medical device technology publications. Connect with him on LinkedIn or email at [email protected].